Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles

Biomaterials

Volumn 34, Issue 26, 2013, Pages 6175-6184

  Qian, Chenchen ^a   Wang, Yong ^a   Chen, Yinting ^a   Zeng, Linjuan ^a   Zhang, Qiubo ^a   Shuai, Xintao ^a,b,c   Huang, Kaihong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c NONE   (China)

Author keywords

Arsenic; CD44v6; Drug delivery; Nanoparticles; Pancreatic cancer; Tumor targeting

Indexed keywords

ARSENIC; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

AMPHIPHILIC DIBLOCK COPOLYMERS; CD44V6; CYTOTOXIC ACTIVITIES; PANCREATIC CANCERS; SINGLE CHAIN VARIABLE FRAGMENTS; SINGLE-CHAIN ANTIBODIES; THERAPEUTIC EFFICACY; TUMOR TARGETING;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE 3; CD44V6 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ETHYLENE GLYCOL; MALEIMIDE; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; ENDOCYTOSIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; UPREGULATION;

ANIMALIA;

EID: 84878665189     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.04.056     Document Type: Article

References (34)

1. Michl P., Gress T.M. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013, 62(2):317-326.
2. Warsame R., Grothey A. Treatment options for advanced pancreatic cancer: a review. Expert Rev Anticancer Ther 2012, 12(10):1327-1336.
3. Kim M.P., Gallick G.E. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 2008, 14(5):1284-1285.
4. Patra C.R., Bhattacharya R., Mukhopadhyay D., Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev 2010, 62(3):346-361.
5. Lim K.H., Chung E., Khan A., Cao D., Linehan D., Ben-Josef E., et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?. Oncologist 2012, 17(2):192-200.
6. Lee J.C., Lee H.Y., Moon C.H., Lee S.J., Lee W.H., Cha H.J., et al. Arsenic trioxide as a vascular disrupting agent: synergistic effect with irinotecan on tumor growth delay in a ct26 allograft model. Transl Oncol 2013, 6(1):83-91.
7. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. NEngl J Med 1998, 339(19):1341-1348.
8. Wang W., Adachi M., Zhang R., Zhou J., Zhu D. Anovel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas 2009, 38(4):e114-e123.
9. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001, 61(14):5432-5440.
10. LaPensee E.W., Ben-Jonathan N. Novel roles of prolactin and estrogens in breastcancer: resistance to chemotherapy. Endocr Relat Cancer 2010, 17(2):R91-R107.
11. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging invivo. Adv Drug Deliv Rev 2013, 65(1):71-79.
12. Hung S.W., Mody H.R., Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 2012, 320(2):138-149.
13. Li Y., Wang J., Wientjes M.G., Au J.L. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012, 64(1):29-39.
14. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol Cell 2011, 31(4):295-302.
15. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7(11):653-664.
16. Bae Y.H. Drug targeting and tumor heterogeneity. JControl Release 2009, 133(1):2-3.
17. Reeder J.A., Gotley D.C., Walsh M.D., Fawcett J., Antalis T.M. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 1998, 58(16):3719-3726.
18. Avoranta S.T., Korkeila E.A., Syrjanen K.J., Pyrhonen S.O., Sundstrom J.T. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol 2012, 18(33):4549-4556.
19. Gun B.D., Bahadir B., Bektas S., Barut F., Yurdakan G., Kandemir N.O., et al. Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diagn Pathol 2012, 7:80.
20. Yang L., Mao H., Wang Y.A., Cao Z., Peng X., Wang X., et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for invivo tumor targeting and imaging. Small 2009, 5(2):235-243.
21. Chen Y., Huang K., Li X., Lin X., Zhu Z., Wu Y. Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability invitro. Cancer Immunol Immunother 2010, 59(6):933-942.
22. Ringel J., Jesnowski R., Schmidt C., Ringel J., Kohler H.J., Rychly J., et al. CD44 in normal human pancreas and pancreatic carcinoma cell lines. Teratog, Carcinog Mutagen 2001, 21(1):97-106.
23. Zambaux M.F., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso M.J., et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. JControl Release 1998, 50(1-3):31-40.
24. Cava-Montesinos P., Cervera M.L., Pastor A., de la Guardia M. Determination of As, Sb, Se, Te and Bi in milk by slurry sampling hydride generation atomic fluorescence spectrometry. Talanta 2004, 62(1):173-182.
25. Nasongkla N., Shuai X., Ai H., Weinberg B., Pink J., Boothman D., et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed 2004, 43(46):6323-6327.
26. Cao N., Cheng D., Zou S., Ai H., Gao J., Shuai X. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32(8):2222-2232.
27. Li X., Ding X., Adrian T.E. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004, 22(3):389-400.
28. Yen Y.P., Tsai K.S., Chen Y.W., Huang C.F., Yang R.S., Liu S.H. Arsenic induces apoptosis in myoblasts through a reactive oxygen species-induced endoplasmic reticulum stress and mitochondrial dysfunction pathway. Arch Toxicol 2012, 86(6):923-933.
29. Zheng C., Zheng M., Gong P., Jia D., Zhang P., Shi B., et al. Indocyanine green-loaded biodegradable tumor targeting nanoprobes for invitro and invivo imaging. Biomaterials 2012, 33(22):5603-5609.
30. Au J.L., Jang S.H., Wientjes M.G. Clinical aspects of drug delivery to tumors. JControl Release 2002, 78(1-3):81-95.
31. Almeida J.P., Chen A.L., Foster A., Drezek R. Invivo biodistribution of nanoparticles. Nanomedicine (Lond) 2011, 6(5):815-835.
32. Liu P., Qin L., Wang Q., Sun Y., Zhu M., Shen M., et al. cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials 2012, 33(28):6739-6747.
33. Lu R.M., Chang Y.L., Chen M.S., Wu H.C. Single chain anti-c-Met antibody conjugated nanoparticles for invivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32(12):3265-3274.
34. Peng X.H., Wang Y., Huang D., Wang Y., Shin H.J., Chen Z., et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 2011, 5(12):9480-9493.